VRTX Articles, Vertex Pharmaceuticals Incorporated - From 02/05/24

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5...

U.S. stock futures experienced a dip in Monday’s premarket session as investors brace for an earnings-heavy week. Federal Reserve Chair ...

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on...

Tuesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 3 program (two Phase 3 trials) for the select...

Markets are primed for a revival in mergers and acquisitions (M&A) in 2024 following the worst performance in almost a decade for deal-making i...

UBS has downgraded Biogen Inc (NASDAQ:BIIB), noting inflection for its second Alzheimer’s drug Leqembi (lecanemab) will take l...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Tuesday, the FDA approved CRISPR Therapeutics AG’s (NASDAQ:CRSP)/Vertex Pharmaceutical Incorporated’s (NASDAQ:VRTX) Casg...

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) sh...

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual ...